UROwebinar: Overtreatment and oversurveillance for low grade NMIBC

ENVISION: UGN-102 and Chemoablation for Low-Grade, Intermediate-Risk NMIBCПодробнее

Urowebinar: New treatments development in NMIBCПодробнее

Dr. Sandip Prasad on ATLAS and ENVISION for Intermediate Risk, Low-Grade NMIBCПодробнее

Management of Non-Muscle Invasive Bladder CancerПодробнее

New bladder cancer treatment would keep bladder intactПодробнее

Very high risk non-muscle-invasive bladder cancer (NMIBC) in the current landscape of NMIBCПодробнее

Non Muscle Invasive Bladder Cancer (NMIBC) OverviewПодробнее

UROwebinar: Patient stratification and risk related treatment of NMIBCПодробнее

Long-term oncological outcomes of office-based fulguration of Ta low-grade NMIBCПодробнее

New treatment of non-muscle-invasive bladder cancerПодробнее

Non-Muscle Invasive Bladder Cancer: Guidelines-Based ApproachПодробнее

Controversies in Non-muscle Invasive Bladder Cancer (NMIBC): Guidelines and Beyond 2023Подробнее

Treatment Talk | Low Grade UTUCПодробнее

UROWebinar: Non neurogenic Female LUTSПодробнее

The evolving landscape in the management of high-risk non-muscle-invasive bladder cancerПодробнее

UROwebinar: Handling adverse events after intravesical instillations in NMIBCПодробнее

UROwebinar: Everything you wanted to know about TURBT: How to handle peculiar situations in TURBПодробнее

UROwebinar: Bladder neoplasms: Will a morphological classification become obsolete?Подробнее